SV

Street Verdict

Analyst Scorecard

A record of what Jay Thakkar said publicly, with the source. Not advice.

Pending — not yet graded
“Suggests buying Zydus Lifesciences futures in the ₹1,170-₹1,180 range, targeting ₹1,250-₹1,300 with a stop-loss below ₹1,130. The stock has seen long built-up as Nifty Pharma reversed, consolidating in the ₹1,100-₹1,250 range. A move above the 1,200 call base could trigger further upside, supported by put additions at lower levels.”

Jay Thakkar’s track record (trackable calls only): 92 graded calls · 95% CI 40–60%

Nifty PharmaBullishCalled 27 Oct 2026
Verdict:PENDING

How this call is judged

A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate. No time frame is stated and the call gives both a target and a stop, so it is tracked until a close reaches one of them (rule H6): the target first is a hit, the stop first a miss, and until then it stays open.

Entry zone: ₹1,170–₹1,180. The call starts at the first close that comes into it.

Target ₹1,250, stop ₹1,130, as stated.

No time frame is stated, so it is tracked until a close reaches ₹1,250 or ₹1,130: there is no fixed window.

Open: tracking until ₹1,250 or ₹1,130 is reached on a close.

This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.

Tracking Nifty Pharma since this call

1-year tracking window
Read the original articleSee Jay Thakkar’s full track record